This trial is testing a combination of two drugs to treat people with urothelial carcinoma who can't take cisplatin. They'll look at how well the drugs work, how long people live, and if there are any side effects.
1 Primary · 3 Secondary · Reporting Duration: Patients are expected to stay on treatment for approximately 12 months; 18 months
39 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: